ADMV方案治疗中晚期非小细胞肺癌62例近期疗效分析

采用ＡＤＭＶ（ＡＤＭ＋ＤＤＰ＋ＭＭＰ＋ＭＭＣ＋ＶＰ－１６）方案联合化疗，对６２例中晚期非小细胞肺癌近期疗效观察，ＣＲ２例，ＰＲ１８例，ＮＲ３２例，ＰＤ１０例， 效率（ＣＲ＋ＰＲ）３２．２６％）２０／６２），化疗毒副反庆主要是消化道反 （５９．６８％）及骨髓抑制（白细胞下降占６１．２９％）．     

APP和VPP联合方案治疗晚期食管癌30例分析

目的：探讨晚期食管ＡＰＰ方案治疗的疗效与毒副作用。方法：ＡＰＰ方案（ＡＤＭ＋ＰＹＭ＋ＰＤＤ）与ＶＰＰ方案（ＶＣＲ＋ＰＹＭ＋ＰＤＤ）对照。结果：ＡＰＰ方案治疗１５例，ＣＲ５例（３３．３３％），ＰＲ４例（２６．７％），Ｓ５例（３３．３％），Ｐ１例（６．７％），有效率（ＣＲ－ＰＲ）６０％。ＶＰＰ方案治疗１５例，ＰＲ８例（５３．３％），Ｓ５例（３３．３％），Ｐ２例＊（１３．４％），有效率（ＣＲ＋ＰＲ）５３     

COMP与PBM化疗方案治疗晚期鼻咽癌的疗效分析

我们以ＣＴＸ＋ＶＣＲ＋ＭＴＸ＋ＤＤＰ（ＣＯＭＰ）和ＤＤＰ＋ＢＬＭ＋ＭＴＸ（ＰＢＭ）两种化疗方案治疗复发和转移的晚期鼻咽癌５８例，４９例可评价客观疗效。结果ＣＯＭＰ组取得了ＣＲ３例，ＰＲ９例，有效率（ＣＲ＋ＰＲ）为５２．２％；ＰＢＭ组ＣＲ１例，ＰＲ９例，有效率（ＣＲ＋ＰＲ）为３８．５％。两者无显著性差异（Ｐ〉０．０５）。治疗后有效病例缓解期为５～５６月，中位缓解期为２５月。两种方案对鼻咽癌肺转移均较     

COMP和PBM化疗方案治疗晚期鼻咽癌的疗效分析

我们以ＣＴＸ＋ＶＣＲ＋ＭＴＸ＋ＤＤＰ（ＣＯＭＰ）和ＤＤＰ＋ＢＬＭ＋ＭＴＸ（ＰＢＭ）两种化疗方案治疗复发和转移的晚期鼻咽癌５８例。４９例可评价客观疗效。结果ＣＯＭＰ组取得ＣＲ３例、ＰＲ９例，有效率（ＣＲ＋ＰＲ）为５２．２％；ＰＢＭ组ＣＲ１例、ＰＲ９例，有效率（ＣＲ＋ＰＲ）为３８．５％。两者无显著性差异（Ｐ＞０．０５）．治疗后有效病例缓解期为５～５６月，中位缓解期为２５月。两种方案对鼻咽癌肺转移均较好，对肝转移疗效最差。ＣＯＭＰ方案对鼻咽癌远处转移疗效较好，对肺转移有效率为５８．３％（７／１２）．可作为鼻咽癌远处转移尤其是肺转移的首选。ＰＢＭ方案对鼻咽癌原灶复发疗效较好，对鼻咽癌复发有效率为４２．９％（３／７），可作为鼻咽癌原灶复发或放射治疗后辅助化疗首选方案。     

用POC方案联合化疗治疗晚期鳞癌48例近期疗效分析

用ＰＯＣ方案（ＰＹＭ，ＶＣＲ，ＣＢＤＣＡ）治疗鳞状细胞癌４８例，其中食管鳞状细胞癌３０例，肺鳞癌１８例。获ＣＲ２例占４．１％，ＰＲ２１例占４３．７％，Ｓ１６例占３３％，Ｐ９例占１９％，有效率（ＣＰ＋ＰＲ）４７．８％。疗效较好，且消化道反应、肾功能损害和神经系统毒性明显减低，因此易为病人接受，有进一步研究的价值。     

VlP与MVP方案治疗非小细胞肺癌的对照研究

目的：通过前瞻性对照研究,比较ＶＩＰ方案与ＭＶＰ方案治疗晚期非小细胞肺癌的疗效及不良反应。方法：共５３例晚期的非小肺癌患者随机入组,治疗应用ＶＩＰ方案（ＶＤＳ＋ＩＦＯ＋ＤＤＰ）,对照组应用ＭＶＰ方案（ＭＭＣ＋ＶＤＳ＋ＤＤＰ）,每例病人至少化疗２疗程。疗效及不良反应评价均按ＷＨＯ标准进行,每例病人随访生存期。结果：治疗组中１例ＣＲ,１５例ＰＲ,８例ＳＤ,１例ＰＤ,有效率（ＣＲ＋ＰＲ）为６４．０％;对     

含顺铂,平阳霉素联合化疗治疗食管癌：（附166例疗效分析）

从１９８３年１１月－１９８９年８月，采用以顺铂、平阳霉素为主，分别与Ｅｔｏｐｏｓｉｄｅ（Ｖｐ－１６），ＶＣＲ，ＭＭＣ，Ｎｉｔｒｏｃａｐｈａｎｅ（ＡＴ－１２５８）结合的ＤＥＰ、ＤＶＰ、ＤＭＰ、ＤＮＰ４种联合化疗方案，随机分组治疗晚期食管癌１６６例，完全缓解（ＣＲ）１４例（８．４％），部分缓解（ＰＲ）７１例（４２．８％），稍效（ＭＲ）４３例（２５．９％），无效（ＮＲ）３８例（２２．９％），有效率（ＣＲ     

帕米膦酸二钠联合153Sm-EDTMP对恶性肿瘤多发骨转移的疗效分析

目的 探讨帕米膦酸二钠（博宁）联合＾１５３Ｓｍ－ＥＤＴＭＰ对恶性肿瘤多发骨转移的临床疗效。方法 ３２例恶性肿瘤多发骨转移患者随机分为２组,每组１６例,分别接受＾１５３Ｓｍ－ＥＤＴＭＰ单独或与帕米膦酸二钠联合治疗。结果 联合组疼痛总缓解率（ＣＲ＋ＰＲ）为９３．８％,单用组为６２．５％,骨病灶控制总有效率（ＣＲ＋ＰＲ）联合组５６．３％,单用组为１８．８％,联合组疗效优于单用组（Ｐ〈０．０５）,两组均无     

博宁联合^153Sm—EDTMP治疗恶性肿瘤多发骨转移的疗效观察

目的：探讨博宁联合＾１５３Ｓｍ－ＥＤＴＭＰ治疗恶性肿瘤多发骨转移的临床疗效。方法：３２例恶性肿瘤多发骨转移患者随机分为２组,每组１６例,分别接受＾１５３Ｓｍ－ＥＤＴＭＰ单独或与博宁联合治疗。结果：联合组疼痛总缓解率（ＣＲ＋ＰＲ）为９３．８％,单用组为６２．５％。骨病灶控制总有效率（ＣＲ＋ＰＲ）联合组５６．３％,单用组为１８．８％,联合组疗效优于单用组（Ｐ〈０．０５）,两组均无严重的毒副作用。结论：     

CHOP与CNOP治疗非何杰金氏淋巴瘤的对比观察报告

ＣＨＯＰ（ＣＴＸ、ＡＤＭ、ＶＣＲ、ＰＤＮ）联合化疗方案是治疗非何杰金氏淋巴瘤（Ｎｏｎ—Ｈｏｄｇｋｉｎ′ｓＬｙｍｐｈｏｍａＮＨＬ）常用的、有效的方法之一。米托蒽醌是一有效的、广谱的、细胞周期非特异性抗癌药，化学结构与阿霉素相似，抗癌活性与ＡＤＭ相当或略高，它无氨基糖结构，心脏毒性较ＡＤＭ低。对确诊为ＮＨＬ３６例住院患者，随机分为ＣＨＯＰ组和ＣＮＯＰ组各１８例作临床对比观察。ＣＨＯＰ组ＣＲ２例、ＰＲ７例，有效率５０％（９／１８）；ＣＮＯＰ组ＣＲ４例、ＰＲ７例，有效率６１．１％（１１／１８），两组疗效相似（Ｐ＞０．０５）。     

以阿霉素为主联合化疗治疗恶性肿瘤62例结果分析

本文分析以阿霉素为主联合化疗治疗晚期恶性肿瘤79例,可评价疗效62例,男54例,女8例,中位数年龄58岁(29～72岁),肺癌48例,胃癌9例,肝癌5例,均为检查确诊的晚期肿瘤患者。肺癌48例中 CR+PR 50%(24/48),胃癌9例 CR+PR11%(1/9)。5例肝癌采用肝动脉插管化疗2～4次,3例达 PR,近期疗效较全身化疗明显提高,主要毒性反应:消化道反应,骨髓抑制和脱发。     

Cisplatin, vinblastine, and bleomycin combination in the treatment of resistant high-risk gestational trophoblastic tumors

Eight patients with high-risk gestational trophoblastic tumors (GTT) resistant to multiagent chemotherapy were treated with the combination of cisplatin, vinblastine, and bleomycin (PVB). All patients had a metastatic disease including three patients with two metastatic sites and two patients with brain metastases. Four patients achieved complete remission (CR) with the PVB regimen (50%). Three additional patients had partial remission (PR) of whom two were converted into CR by surgery of resistant residual lesions. One patient relapsed and the remaining five patients in CR were cured (62%). A multimodal approach was necessary in most patients as five of them had hysterectomy and two patients had a whole-brain irradiation. Toxicity was mild with no treatment related deaths.     

三维适形放疗技术在恶性肿瘤治疗中的应用

目的分析三维适形放疗治疗的临床应用价值。方法采用三维适形放疗治疗恶性肿瘤63例,其中常规外照射0Gy-40Gy、适形剂量2.0Gy-3.0Gy/每次,每日1次,每周5次,肿瘤局部应用总剂量:54Gy-76Gy(中位剂量62Gy)。结果CT显示完全缓解8.0%(5/63),部分缓解70%(44/63),总有效率78%(49/63)。全部病例未发生Ⅱ级以上急性反应。结论三维适形放疗对恶性肿瘤疗效确切,不良反应可耐受。     

Phase II study of palliative low-dose local radiotherapy in disseminated indolent non-Hodgkin's lymphoma and chronic lymphocytic leukemia

: Indolent non-Hodgkin’s lymphoma (INHL) and chronic lymphocytic leukemia (CLL) are highly sensitive to radiotherapy (RT). Previous retrospective studies have shown high response rates after local palliative RT of 4 Gy in 2 fractions, which prompted this prospective Phase II trial of the palliative effect of this regimen in patients with disseminated INHL or CLL.

: Twenty-two patients (11 men, 11 women, median age 62 years, range 30–89) with disseminated INHL (n = 15) or CLL (n = 7) were treated with local low-dose RT, 2 Gy × 2 within 3 days, with the aim of achieving palliation from localized lymphoma masses. The patients were treated to a total of 31 different sites. Seventeen patients had previously been treated with chemotherapy. The median observation time after the start of RT was 8 months (range 3–26).

: All patients and all irradiated sites were assessable for response. Of the 22 patients, 18 responded to the treatment, corresponding to an overall response rate (RR) of 82%; 12 patients (55%) achieved a complete response (CR), 5 patients (22%) a partial response (PR), and 1 patient had a CR at three sites and a PR at one site. Of the 31 irradiated sites, 27 responded to treatment, corresponding to an overall RR of 87%; in 20 sites (65%) a CR was achieved and in 7 sites (22%) a PR. Patients with disseminated INHL had an overall RR of 87% (74% CR, 13% PR); patients with CLL had an overall RR of 71% (29% CR, 42% PR). The median duration of response was estimated at 22 months. None of the patients had significant side effects from the treatment.

: Low-dose RT (4 Gy in 2 fractions) is a highly effective palliative treatment of localized lymphoma masses in patients with disseminated INHL and CLL. The treatment has minimal side effects.     

Single 4 Gy re-irradiation for painful bone metastasis following single fraction radiotherapy.

PURPOSE: to investigate effectiveness of a single-fraction of 4 Gy given for re-treatment of bone metastasis after previous single-fraction radiotherapy (RT). MATERIAL AND METHODS: Of 135 patients retreated, 109 patients were retreated because of pain relapsing after 4 Gy (group I, n = 34), 6 Gy (group II, n = 39), or 8 Gy (group III, n = 36), while 26 patients were re-irradiated after initial non-response (group I, n = 12; group II, n = 8; group III, n = 6). RESULTS: Of the 109 patients that were re-irradiated for pain relapse, 80 (74%) patients responded (complete response (CR) = 31%; partial response PR) = 42%). Among the 26 patients that initially did not respond, there were 12 (46%) responses. Patients with previous CR were more likely to achieve CR than were patients with previous PR (P = 0.042). No such finding was observed for obtaining PR, which was achieved in 45% each of patients previously having either CR or PR (P = 0.99). Patients with previous CR had similar chance to obtain either CR or PR (P = 0.65), while previous PR influenced subsequent response in the way of achieving more PRs than CRs (P = 0.00054). Combined, these data showed that patients with initial CR were more likely to respond than those with previous PR (85% vs. 67%, P = 0.037). There were no difference between the three initial treatment groups regarding the efficiency (CR or CR + PR) of second RT. Toxicity was low and only gastrointestinal. CONCLUSIONS: Single-fraction RT consisting of 4 Gy was effective and little toxic treatment that could be administered after previous single-fraction RT.     

根据肿瘤细胞药敏结果指导治疗急性白血病40例

 目的：了解肿瘤细胞药敏试验在治疗急性白血病中的临床意义。方法：取患者外周血或骨髓2ML进行离心、冲洗干燥处理后进行计数。结果：治疗组40例，32例获完全缓解，其中19例一疗程完全缓解，13例2疗程完全缓解，完全缓解率30%。2例部分缓解。对照组35例中22例完全缓解，完全缓解率为62.8%，6例部份缓解，二组完全缓解率对比有显著性差异(0.05>P>0.01)。结论：根据肿瘤细胞药敏结果指导治疗急性白血病疗效满意。     

Retreatment with the induction regimen in small cell lung cancer relapsing after an initial response to short term chemotherapy

In 37 patients with small cell lung cancer treatment with five cycles of cyclophosphamide, doxorubicin and etoposide (CDE), resulted in 23 complete (CR) and 14 partial responses (PR). Median response duration was 34 weeks. At relapse all patients were retreated with CDE. In 23 (62%) patients this gave a second response (6 CR, 17 PR). Factors influencing the occurrence of a second response were:

• 1.1. a CR after the first five cycles of CDE; 18 out of 23 CR patients responded again whereas only five of the 14 PR patients responded (P < 0.01).
• 2.2. 15 out of 19 patients with a first response duration > 34 weeks reached a second response and in eight of the other 18 patients retreatment was successful (P < 0.05).

Reinduction at relapse, after short term chemotherapy and a treatment-free interval, with the induction regimen is an effective second line treatment in patients with an initial CR and a first response duration of > 34 weeks.     

Clinical study of HCFU in combination with irradiation therapy in squamous cell carcinoma of the head and neck

Sixty-two patients with squamous cell carcinoma of the head and neck were administered a mean total dose of 75.9 g carmofur (HCFU) in combination with a mean total dose of 49.0 Gy irradiation therapy. The primary sites of cancer were: larynx 29 cases, oral cavity 11 cases, nasal and paranasal cavity 7 cases, hypopharynx 5 cases, nasopharynx 5 cases, epipharynx 3 cases, and others 2 cases. The clinical stages were: stage I II cases, stage II 15 cases, stage III 17 cases, and stage IV 19 cases. In 57 evaluable patients having measurable lesions, overall response rate, including 26 complete responses (CR) and 16 partial responses (PR), was 73.7%. Average doses of HCFU were 13.1 g at PR, 27.8 g at CR, and those of irradiation were 27.7 Gy at PR, 48.5 Gy at CR. The median duration of PR was 44.8 weeks and that of CR was 47.0 weeks, the overall response interval being 47.7 weeks. Of the 62 patients, 25 (40.3%) complained of side effects including pollakisuria (9 cases), appetite loss (6 cases), stomatitis (5 cases), and so on.     

Prospective study with HEXA-CAF combination in ovarian carcinoma

Summary The value of combination chemotherapy with HEXA-CAF was analyzed in 31 patients with histologically documented epithelial ovarian cancer in advanced stages (minimal or gross disease). No patient had been previously treated with chemotherapy. Peritoneoscopy with diaphragmatic inspection, peritoneal cytology, lymphography, and chest X-ray were routinely used in staging and restaging the patients. Complete (CR) plus partial (PR) responses were obtained in 13/31 fully restaged patients (41.9%). CR was recorded in seven patients (22.5%) and PR in six patients (19.3%). Remission duration was significantly longer in patients who achieved CR (20 months) than in those who attained PR (9.5 months)(P<0.01). In all treated patients the median duration of survival was 16.5 months. Survival was significantly longer in patients with CR than in patients who did not achieve CR (P<0.05). Nevertheless, considering the rate of CR in patients with gross disease (20.6%), HEXA-CAF combination seems a useful but not yet ahopeful treatment for patients with advanced ovarian carcinoma.     

Carboplatin (CBDCA, JM-8) and VP-16-213 in previously untreated patients with small-cell lung cancer

The efficacy and toxicity of carboplatin 100 mg/m2, administered intravenously (IV) daily X 3, and VP-16-213 120 mg/m2, IV daily X 3, administered every 28 days for six courses, was assessed in 94 (36 limited stage, 58 extensive stage) previously untreated patients with small-cell lung cancer. Mediastinal irradiation using 50 Gy in 25 fractions was given to all limited-stage patients with a complete (CR) or partial response (PR) after three chemotherapy courses. Cranial irradiation was administered to all patients with CR. Objective responses were seen in 77% (CR 40%, PR 37%) of patients with limited-stage and 58% (CR, 9%; PR, 49%) with extensive-stage disease. Median relapse-free survival for objective responders with limited stage was 14.6 months and 7.9 months for extensive-stage patients. Median relapse-free survival following CR was 15.4 months and 8.5 months for PR. Median survival was 15.3 months for limited-stage and 8.1 months for extensive-stage patients. The combination was well tolerated with mild nausea or less (World Health Organization [WHO] grade 0 or 1) in 62% of patients and minimal mucositis, renal, neurotoxicity, or ototoxicity. Neutropenia less than 1.0 X 10(9)/L (WHO grade 3 or 4) was seen in 63% of patients, with two deaths from infection while neutropenic. The combination of carboplatin and VP-16-213 is a new, active program with low toxicity when applied intensively in previously untreated patients with small-cell lung cancer.